Scarica l'app Stockscreener
6.15
4.80%
-0.31
Dopo l'orario di chiusura:
6.16
0.010
+0.16%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.46
Aprire:
$6.46
Volume 24 ore:
945.89K
Relative Volume:
0.55
Capitalizzazione di mercato:
$523.57M
Reddito:
$11.40B
Utile/perdita netta:
$-95.73M
Rapporto P/E:
-2.5102
EPS:
-2.45
Flusso di cassa netto:
$-64.37M
1 W Prestazione:
-11.26%
1M Prestazione:
+8.27%
6M Prestazione:
-27.56%
1 anno Prestazione:
-32.57%
Intervallo 1D:
$6.03
$6.5253
Intervallo di 1 settimana:
$6.03
$6.9096
Portata 52W:
$4.70
$10.44
Mind Medicine Inc Stock (MNMD) Company Profile
Nome
Mind Medicine Inc
Settore
Industria
Telefono
212-220-6633
Indirizzo
ONE WORLD TRADE CENTER, NEW YORK
Confronta MNMD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MNMD
Mind Medicine Inc
|
6.15 | 523.57M | 11.40B | -95.73M | -64.37M | -2.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-28 | Iniziato | Evercore ISI | Outperform |
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-07-24 | Iniziato | ROTH MKM | Buy |
| 2024-05-29 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-15 | Iniziato | Leerink Partners | Outperform |
| 2023-12-05 | Iniziato | Canaccord Genuity | Buy |
| 2022-12-09 | Ripresa | ROTH Capital | Buy |
| 2022-11-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-08-26 | Iniziato | Oppenheimer | Outperform |
| 2022-08-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-05-04 | Iniziato | ROTH Capital | Buy |
| 2021-06-28 | Iniziato | Maxim Group | Buy |
Mostra tutto
Mind Medicine Inc Borsa (MNMD) Ultime notizie
Psychedelic: Compass, GH Research, MindMed report quarterly earnings - Yahoo Finance
Mind Medicine (MNMD) Rating and Price Target Maintained by Chardan Capital | MNMD Stock News - GuruFocus
Rising Leaders 2025: Rob Barrow On Leading MindMed’s Psychedelic Renaissance - insights.citeline.com
Mind Medicine Inc (MNMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amidst Financial ... - Yahoo Finance
Mind Medicine Inc (MNMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amidst Financial Challenges - GuruFocus
MindMed Advances Phase 3 Trials for Brain Health - TipRanks
Transcript : Mind Medicine Inc., Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
MindMed Advances Phase 3 Trials for Brain Health Treatments - TipRanks
MindMed Q1 2025 slides: Phase 3 trials advance as cash position remains strong - Investing.com Australia
Earnings call transcript: MindMed Q1 2025 results show mixed signals By Investing.com - Investing.com UK
MindMed (MNMD) Advances Phase 3 Trials with Growing Enthusiasm | MNMD Stock News - GuruFocus
Mind Medicine (MindMed) Inc. SEC 10-Q Report - TradingView
MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates - The Joplin Globe
(MNMD) Long Term Investment Analysis - news.stocktradersdaily.com
MindMed to Report First Quarter 2025 Financial Results on May 8, 2025 | MNMD Stock News - GuruFocus
Great week for Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) institutional investors after losing 28% over the previous year - simplywall.st
MindMed to Report First Quarter 2025 Financial Results on May 8, 2025 - Business Wire
Mind Medicine: Strong Data, But Psychedelic Stigma Still Clouds Investor Confidence - Seeking Alpha
Institutional investors own a significant stake of 50% in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - Yahoo Finance
Mind Medicine (Mindmed) IncMindmed Enters Into First Amendment To Loan And Security AgreementSEC Filing - marketscreener.com
MindMed Announces New Employee Inducement Grants | MNMD Stock Ne - GuruFocus
MindMed Announces New Employee Inducement Grants | MNMD Stock News - GuruFocus
MindMed Announces New Employee Inducement Grants - Business Wire
Lobbying Update: $100,000 of MIND MEDICINE (MINDMED) INC. lobbying was just disclosed - Nasdaq
Mind Medicine: Initiating Hold Rating Due To Regulatory Challenges (NASDAQ:MNMD) - Seeking Alpha
How the (MNMD) price action is used to our Advantage - news.stocktradersdaily.com
Broadway Gold Mining : MindMed Promotes Jeanne Bonelle to Executive Vice President, Technical Operations - marketscreener.com
MindMed Begins Phase 3 Study of MM120 for Major Depressive Disorder - TipRanks
Oppenheimer maintains MindMed stock Outperform with $20 target By Investing.com - Investing.com India
MindMed launches phase 3 LSD study for depression By Investing.com - Investing.com Nigeria
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD) - GuruFocus
MindMed launches phase 3 LSD study for depression - Investing.com Australia
MindMed Announces First Patient Dosed in Phase 3 Emerge Study of - GuruFocus
Mindmed Announces First Patient Dosed In Phase 3 Emerge Study Of Mm120 In Major Depressive Disorder (Mdd) - marketscreener.com
Breakthrough: First-Ever Phase 3 LSD Depression Trial Begins at MindMed - Stock Titan
MindMed Appoints Schond L. Greenway as Chief Financial Officer - MarketScreener
MNMD stock touches 52-week low at $5.03 amid market challenges - Investing.com India
Long Term Trading Analysis for (MNMD) - news.stocktradersdaily.com
MNMD stock touches 52-week low at $5.03 amid market challenges By Investing.com - Investing.com South Africa
MNMD Stock Forecast From 2025 To 2040 - Exla Resources
Mind Medicine CEO Robert Barrow sells shares worth $142,941 By Investing.com - Investing.com India
MindMed Advances Clinical Programs with Strong Financial Backing - TipRanks
Mind Medicine CEO Robert Barrow sells shares worth $142,941 - Investing.com
MindMed Strengthens Brain Health Pipeline with Key Technical Talent Acquisition - Stock Titan
Generalized Anxiety Disorder Treatment Market Size in 7MM - openPR
MindMed appoints new Chief Commercial Officer By Investing.com - Investing.com South Africa
MindMed Appoints Matt Wiley as Chief Commercial Officer - Quantisnow
MindMed appoints new Chief Commercial Officer - Investing.com
Mind Medicine Inc Azioni (MNMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.84%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):